These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16153857)

  • 41. Regulatory T cells in immune surveillance and treatment of cancer.
    Yamaguchi T; Sakaguchi S
    Semin Cancer Biol; 2006 Apr; 16(2):115-23. PubMed ID: 16376102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune cells as anti-cancer therapeutic targets and tools.
    Johansson M; Tan T; de Visser KE; Coussens LM
    J Cell Biochem; 2007 Jul; 101(4):918-26. PubMed ID: 17265430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology.
    Nicolini A; Carpi A
    Med Res Rev; 2009 May; 29(3):436-71. PubMed ID: 19105214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
    Wesa AK; Storkus WJ
    Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The resolution of inflammation and cancer.
    Rodriguez-Vita J; Lawrence T
    Cytokine Growth Factor Rev; 2010 Feb; 21(1):61-5. PubMed ID: 20022797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Plasmapheresis in the patients with malignant tumor].
    Kodama M; Tani T; Nakane Y
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1349-55. PubMed ID: 6378099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-tumor immunity and mechanism of immunosuppression mediated by tumor cells: role of tumor-derived soluble factors and cytokines.
    Deepak P; Acharya A
    Int Rev Immunol; 2010 Aug; 29(4):421-58. PubMed ID: 20635882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unravelling the complexity of cancer-immune system interplay.
    Fraser CK; Brown MP; Diener KR; Hayball JD
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):917-34. PubMed ID: 20553215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sarcomas and the immune system: implications for therapeutic strategies.
    Francescutti V; Skitzki JJ
    Surg Oncol Clin N Am; 2012 Apr; 21(2):341-55. PubMed ID: 22365524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the impact of pro- and antiinflammatory immune processes at the two immune-deviated sites, eye and solid tumor and possible consequences for the antitumoral therapy with fever inducers.
    Schramm H
    Forsch Komplementarmed Klass Naturheilkd; 2005 Feb; 12(1):37-46. PubMed ID: 15772461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune selection in neoplasia: towards a microevolutionary model of cancer development.
    Pettit SJ; Seymour K; O'Flaherty E; Kirby JA
    Br J Cancer; 2000 Jun; 82(12):1900-6. PubMed ID: 10864195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Eighteen-year experience of cancer immunotherapies--evaluation of their therapeutic benefits and future].
    Torisu M; Uchiyama A; Goya T; Iwasaki K; Katano M; Yamamoto H; Kimura Y
    Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1212-6. PubMed ID: 1944189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth.
    al-Sarireh B; Eremin O
    J R Coll Surg Edinb; 2000 Feb; 45(1):1-16. PubMed ID: 10815374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.
    Hwang I; Nguyen N
    Arch Pharm Res; 2015 Aug; 38(8):1415-33. PubMed ID: 25634101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cellular automaton model of cancerous growth.
    Qi AS; Zheng X; Du CY; An BS
    J Theor Biol; 1993 Mar; 161(1):1-12. PubMed ID: 8501923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.